Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37870487.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2437 and PMC identifier 10842335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade. See related article by Weiss et al., p. 74.
Medical subject headings
- CD40 Antigens
- Immune Checkpoint Inhibitors